Bharat Biotech gets nod from DCGI panel for Phase III trials of Covaxin
The recommendation is after assessing data from Phase I & II as well as animal challenge study
Over 25,000 people are expected to enroll for the human trials
Each will be given two doses of the experimental vaccine 28 days apart
Currently, Bharat Biotech is conducting Phase II human trials
